Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday’s intraday trade. This came after the ...

Biocon shares rose 9% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab. Jefferies upgraded its rating to 'Hold' with a target of ₹400, citing ...

CCI fines Goldman Sachs for undisclosed investment in Biocon, highlighting need for compliance with competition laws in ...

BRIDGEWATER, N.J., and BENGALURU, India, Jan. 9, 2025 /PRNewswire/ --Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523 ...

After the clearance from US drugs regulator, Motilal Oswal has upgraded Biocon to 'buy' with a target price of Rs 430 apiece.

The Competition Commission penalises Goldman Sachs AIFs investment manager Rs 40 lakh for not notifying the Biocon deal, ...

Analysts said that assuming a $700 million market size for gAspart, Biocon can see US sales worth $25 million and $50 million ...

India's Competition Commission has penalized Goldman Sachs' investment manager for not notifying a deal to acquire a stake in ...

Josh Gissing is Cluster Head (UK, Ireland & Nordics) for Biocon Biologics: a biosimilars company whose business model seeks ...

The Competition Commission of India (CCI) has fined Goldman Sachs AIF's investment manager Rs 40 lakh for not notifying a ...

Bengaluru: Biocon has announced that the U.S. Food and Drug Administration (FDA) has classified Biocon Biologics' Insulins ...

Motilal Oswal is bullish on Biocon recommended buy rating on the stock with a target price of Rs 430 in its research report ...